11:35 AM
Dec 05, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Pancreatic cancer; melanoma

Cell culture and mouse studies suggest inhibiting MHCI, MHCI components or the macrophage MHC1 binding partner LILRB1 could help treat pancreatic cancer and melanoma. In co-culture of human pancreatic neuroendocrine tumor cell lines and macrophages, a combination of antibodies against CD47 and LILRB1 increased cancer cell phagocytosis compared with the anti-LILRB1 antibody alone. In a xenograft mouse model...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >